The role of high-dose chemotherapy in relapsed germ cell tumors

World Journal of Urology

Volumn 22, Issue 1, 2004, Pages 25-32

  Rick, O ^a   Kollmannsberger, C ^b   Hartmann, J T ^b   Braun, T ^a   Siegert, W ^a   Bokemeyer, C ^b   Beyer, J ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Germ cell tumor; High dose chemotherapy; Relapse or progressive disease

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; DOSE RESPONSE; GERM CELL TUMOR; HUMAN; PALLIATIVE THERAPY; PROGNOSIS; REVIEW; SALVAGE THERAPY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMINOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PROGNOSIS; SALVAGE THERAPY;

EID: 4344569031     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0396-x     Document Type: Review

References (51)

1. Bosl G, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337:242-253
2. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603
3. Harstrick A, Schmoll HJ, WilkeH, Kohne-Wompner CH, Stahl M, Schober C, Casper J, Bruderek L, Schmoll E, Bokemeyer C (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9:1529-1535
4. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540-546
5. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19:81-88
6. Rick O, Siegert W, Beyer J (1999) High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany. Int J Cancer 83:839-840
7. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15:1427-1431
8. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol;18:2413-2418
9. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18:1173-1180
10. Rodenhuis S, DeWit R, DeMulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker P, Mandjes I, Kooi M, DeVries EG (1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10:1467-1473
11. Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH (2000) High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351
12. Beyer J, Stenning S, Gerl A, Fossa SD, Siegert W (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13:599-605
13. Rosti G, Pico JL, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Schmoll HJ, Linkesch W, Pizzocaro G, Bouzy J, Kramar A, Droz JP Biron P (2002) High-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors; first results of a prospective randomised trial of the European Group for Blood and Morrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol 21:716
14. Nichols CR, Tricot G, Williams SD, Van-Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN (1989) Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939
15. Broun ER, Nichols CR, Gize G (1997) Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79:1605-1610
16. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14:2638-2645
17. Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12:1390-1393
18. Vaena DA, Abonour R, Einhorn LH (2003) Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21:4100-4104
19. Hartmann JT, Bamberg M, Albers P, Clemm C, Souchon R, Oechsle K, Weissbach L, Kanz L, Bokemeyer C for the GTCSG-CNS Working Group (2003) Multidisciplinary treatment and prognosis of patients with central nervous system metastases from testicular germ cell tumor origin. Proc Am Soc Clin Oncol 22:400
20. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA (1999) Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80:1392-1399
21. Donohue JP, Birhle R, Foster RS (1992) Evolving concepts in surgical management of testis cancer. Cancer Treat Res 59:89-97
22. Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, EinhornLH (1993) Outcome analysis of patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11:1294-1299
23. De-Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J (2001) Predictive impact of 2-fluoro-2-deoxy-D- glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19:3740-3744
24. Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Braun T, Rachud B, Weißbach L, Hartmann M, Siegert W, Beyer J (2004) Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol (in press)
25. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular cell tumors. Ann Oncol 8:531-538
26. Donohue JP, Fox EP, Williams SD, Loehrer PJ, Ulbright TM, Einhorn LH, Weathers TD (1994) Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 12:190-195
27. Peckham MJ, Horwich A, Easton DF, Hendry WF (1988) The management of advanced testicular teratoma. Br J Urol 62:63-68
28. Fossa, SD, Aass N, Ous S, Hoie J, Stenwig AE, Lien HH, Paus E, Kaalhus O (1989) Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 142:1239-1242
29. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue J (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13:1177-1187
30. Steyerberg EW, Gerl A, Fossa SD, Sleijfer DT, DeWit R, Kirkels WJ, Schmeller N, Clemm C, Habbema JD, Keizer HJ (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16:269-274
31. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de-Bono JS, Stenning S, Horwich A, Pont J, Albers P, De-Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 19:2647-2657
32. Loehrer PJ, HuiS, Clark S, Seal M, Einhorn LH, Williams SD, Ulbright T, Mandelbaum I, Rowland R, Donohue JP (1986) Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol 135:1183
33. Tait D, Peckham MJ, Hendry WF, Goldstraw P (1984) Postchemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: The significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50:601-609
34. Gerl A, Clemm C, Schmeller N, Dienemann H, Lamerz R, Kriegmair M, Wilmanns W (1995) Outcome analysis after postchemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6:483-438
35. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE, Wilkinson PM (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumor Working Party. Cancer 83:1409-1419
36. Pizzocaro G, Nicolai N, Milani A, Piva L, Merson M, Colavita M, Salvioni R (1998) Is further chemotherapy necessary in radically resected residual cancer in non-seminomatous germ cell tumors (NSGCT) of the testis following induction chemotherapy. Proc Am Soc Clin Oncol 17: abstract
37. Cooper M, Einhorn LH (1995) Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 13:1167-1169
38. Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18:1181-1186
39. Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34
40. Loehrer PJ (1991) Etoposide therapy for testicular cancer. Cancer 67:220-224
41. Bokemeyer C, Beyer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31-34
42. Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512-516
43. Einhorn LH, Slender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17:509-511
44. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schöffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031-2037
45. Hinten S, Catalano PJ, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D, Wilding G (2001) Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 20:1859-1863
46. Bokemeyer C, Beyer J, Metzner B, Schöffski P, Liersch R, Rick O, Stengele K, Spott C, Kanz L, Kollmannsberger C (2003) Combination chemotherapy with gemcitabine/oxaliplatin in patients with relapsed or cisplatin-Refraktor germ-cell cancer. Proc Am Soc Clin Oncol 22:389
47. Linkesch W, Krainer M, Wagner A (1992) Phase I/II trial of ultrahigh dose carboplatin, etoposide, cyclophosphamide with ABMT in refractory nonseminomatous germ cell tumors (GCT). Proc Am Soc Clin Oncol 11: abstract
48. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V (1996) High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105
49. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12:1223-1231
50. Rick O, Beyer J, Kingreen D, Schwella N, Krusch A, Schleicher J, Kirsch A, Huhn D, Siegert W (1998) High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer 34:1883-1888
51. Rick O, Kollmannsberger C, Beyer J, Bokemeyer C (2003) Current aspects of high-dose chemotherapy in germ-cell tumors. Crit Rev Oncol Hematol 47:237-248